Metrics as of 10/16/2026, 09:19 PM (Berlin time), refresh in progress.
Grifols Stock
Grifols, S.A.
Company data
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Country
- Spain
- CEO
- Jose Ignacio Abia Buenache
- Employees
- 25,258
- Market cap
- $6.5 B
- IPO
- 02/06/2011
Grifols, S.A., founded in 1940 and headquartered in Barcelona, Spain, is a healthcare company specializing as a drug manufacturer. The company focuses on the development, manufacture, and distribution of therapeutic products, with a primary emphasis on those derived from human plasma. Its operations are organized into…
Company description based on the data provider's company data, AI-assisted, created on 16/10/2026. Not investment advice.
Grifols stock: price history
1D
+2.4%
1W
+3.5%
1M
+4.3%
6M
-11.8%
YTD
-17.4%
1Y
-20.8%
2Y
-9.1%
5Y
-45.7%
10Y
-48.7%
Next earnings date
Next earnings date
10/11/2026 (in 24 days)
Volatility around earnings
~66% stronger price swings than usual
Pattern chart
Pattern detected by the Market Jury detector vsqueeze-release-v1.0 on 16/10/26. Not a buy or sell signal.Beta
What does this mean?
Volatility squeeze
BullishPrice swings had compressed unusually tight beforehand (volatility near a low) and are now releasing into a stronger move. Technical analysis views such tight phases as often preceding a bigger move.
Chart patterns are a purely technical signal derived from price action. At Market Jury they do not feed into the agents' buy or sell decisions, they are supplementary information only.
Grifols stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 17/10/2026.
Ask the agents about Grifols
Analyst assessment of Grifols
0
STRONG BUY
4
BUY
2
HOLD
2
SELL
0
STRONG SELL
8
TOTAL · Buy
As of: 08/12/2025
Grifols stock metrics
P/E
15.19
P/B
1.25
EV/EBITDA
8.54
RETURN ON EQUITY
2.8%
NET MARGIN
8.2%
DEBT/EQUITY
1.54
DIVIDEND YIELD
0.8%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
98.7%
FLOAT SHARES
834,630,340
AVG. DAILY VOLUME (30D)
577,333
Institutional holders
Dividends & Stock splits
Dividends
Stock splits
Smart Money
Register for free
Register now to see which funds are invested
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Comparable stocks
Frequently asked questions about Grifols stock
What does Grifols do?
Grifols, S.A. is a company in the Healthcare sector, Drug Manufacturers - General industry, headquartered in Spain.
The CEO is Jose Ignacio Abia Buenache, the company employs around 25,258 people.
The IPO was on 02/06/2011; the stock trades on NASDAQ under the ticker GRFS.
What do analysts say about Grifols stock?
8 analysts rate the stock, the consensus is Buy (as of 08/12/2025).
This is an external assessment, not a statement by Market Jury.
When does Grifols report next?
The next earnings date is 10/11/2026.
Around past earnings, price swings were roughly 66% stronger than usual.
Does Grifols pay a dividend?
Yes. The last dividend was US$0.11 per share, ex-date 02/07/2026, paid on 09/07/2026.
The dividend yield is 0.8% (as of 30/06/2026).
Which stocks are comparable to Grifols?
Comparable stocks include Eli Lilly and Company, Johnson & Johnson, AbbVie, Merck &, Roche Holding, Amgen, Gilead Sciences and Pfizer.
How can I get Grifols stock analyzed?
Clicking "Analyze stock" lets five strategies assess Grifols against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.